RU1837891C - Method for preparation antitumor agent - Google Patents

Method for preparation antitumor agent

Info

Publication number
RU1837891C
RU1837891C SU914905853A SU4905853A RU1837891C RU 1837891 C RU1837891 C RU 1837891C SU 914905853 A SU914905853 A SU 914905853A SU 4905853 A SU4905853 A SU 4905853A RU 1837891 C RU1837891 C RU 1837891C
Authority
RU
Russia
Prior art keywords
preparation
antitumor agent
iron
preparation antitumor
irradiated
Prior art date
Application number
SU914905853A
Other languages
Russian (ru)
Inventor
Виктор Владимирович Кешелава
Анатолий Васильевич Бушуев
Original Assignee
Keshelava Viktor V
Bushuev Anatolij V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keshelava Viktor V, Bushuev Anatolij V filed Critical Keshelava Viktor V
Priority to SU914905853A priority Critical patent/RU1837891C/en
Priority to PCT/RO1992/000024 priority patent/WO1992013563A1/en
Application granted granted Critical
Publication of RU1837891C publication Critical patent/RU1837891C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Способ получени  противоопухолевого средства. Область использовани : изобретение относитс  к медицине, а именно к онкологии и иммунологии. Цель: повышение активности конечного продукта. Сущность изобретени : препараты железа облучают потоком нейтронов. Положительный эффект: полученный препарат оказывает общее и локальное действие, а также высокую эффективность при лечении.A method of preparing an antitumor agent. Field of use: the invention relates to medicine, namely to oncology and immunology. Goal: increase the activity of the final product. SUMMARY OF THE INVENTION: iron preparations are irradiated with a neutron flux. Positive effect: the resulting preparation has a general and local effect, as well as high efficiency in treatment.

Description

Изобретение относитс  к медицине и ожет примен тьс  в онкологии, ИММУНОЛОГИ .The invention relates to medicine and can be used in oncology, IMMUNOLOGISTS.

Рентгеновское излучение и радиоактив- ые вещества используютс  с лечебной и иагностической целью.X-rays and radioactive substances are used for therapeutic and diagnostic purposes.

Изобретение-позвол ет получить пре- арат дл  лечени  как онкологических, так и ммунных заболеваний, основанного на аспространении радиоактивного препара- с изотопом 59Fe током крови по всему рганизму и накоплении его в опухолевой они и метастазах.The invention allows to obtain a medication for the treatment of both oncological and immune diseases, based on the spread of the radioactive drug with the 59Fe isotope by blood flow throughout the whole organism and its accumulation in tumor and metastases.

Средство получают путем активации же- езосодержащего препарата нейтронами.The agent is obtained by activating the iron-containing preparation with neutrons.

Пример 1 Исходный препарат Фер- о-градумент. Example 1 Starting preparation Fer-o-degree.

Таблетка препарата сЬдержит 525 фер- о-сульфата, что соответствует 105 мг эле- ентарного железа.A tablet of the preparation contains 525 fero-sulfate, which corresponds to 105 mg of elemental iron.

Облучали в канале тепловой колонны сследовательскогб реактора ИРТ потокомIrradiated in the channel of the heat column of the IRT research reactor

ейтронов 5 1011 Ч в течение 24 ч.neutrons 5 1011 H for 24 hours

Наведенна  радиоактивность одной аблетки составила около одного микрокю- 59Fe. Спуст  3-4 дн  после завершени  блучени  радиоактивность всех других ра- иоактивных нуклидов (изотопов натри .The induced radioactivity of one ablette was about one micro-59Fe. 3-4 days after the completion of the boiling, the radioactivity of all the other radioactive nuclides (sodium isotopes).

хрома/ кроме 59Fe спадала до незначительного уровн  что делало препарат пригодным дл  применени .chromium / except for 59Fe decreased to an insignificant level, which made the preparation suitable for use.

Пример 2. Исходный препарат Тар- диферон.Example 2. Starting preparation Tardiferon.

Таблетка препарата содержит сульфата железа 11 безводного 256,2 мг(80 мг. элементарного железа), мукопротеазу 80 мг. Облучают по примеру 1. Наведенна  радиоактивность 0,8 микрокюри 59Fe. На 3- 4 сутки после облучени  вредных примесей не вы влено. Препарат пригоден дл  употреблени .The tablet of the preparation contains iron sulfate 11 anhydrous 256.2 mg (80 mg. Elemental iron), mucoprotease 80 mg. Irradiate according to example 1. Induced radioactivity of 0.8 microcurie 59Fe. On 3-4 days after irradiation, no harmful impurities were detected. The preparation is suitable for consumption.

Пример 3. Исходный препарат Гемо- стиМулин.Example 3. The initial preparation GemostiMulin.

Таблетка препарата содержит 0,246 г лактата железа, 0,005 сульфата меди, Облучают по примеру 1. Наведенна  радиоактивность 0,5 микрокюри Fe. На 3-4 сутки после облучени  вредных примесей нет. Препарат пригоден дл  применени .The tablet of the preparation contains 0.246 g of iron lactate, 0.005 copper sulfate. Irradiate in example 1. Induced radioactivity of 0.5 microcurie Fe. 3-4 days after irradiation, there are no harmful impurities. The preparation is suitable for use.

Пример 4. Исходный препарат Фер- рум-лек.Example 4. The starting preparation Ferrum-Lek.

В 1 ампуле 0,1 гтрехвалентнго железа а комплексе с мальтозой. Облучают по примеру 1. Наведенна  радиоактивность 0,2 микрокюри 9Fe. Вредных примесей на 4 сутки нет. Препарат пригоден дл  применени .In 1 ampoule of 0.1 g of ferric iron and complex with maltose. Irradiate in example 1. Induced radioactivity of 0.2 microcurie 9Fe. There are no harmful impurities on the 4th day. The preparation is suitable for use.

ЁYo

0000

со- VJco vj

00 Ч)00 h)

соwith

Пример 5. Исходный препарат Фер- ро-градумент.Example 5. Starting preparation Ferro-degree.

1 таблетка содержит 525 мг ферро-суль- фата (105 мг.элемент.железа). Облучали в вертикальном экспериментальном канале реактора ИТР потоком нейтронов плотностью 51011 нейтр./см2 с, в течение 48 ч. Наведенна  радиоактивность 10 микрокюри 59Fe. Препарат пригоден дл  применени  через 4-5 дней после облучени .1 tablet contains 525 mg of ferrosulphate (105 mg. Element. Iron). The neutron flux of 51011 neutrons / cm2 s was irradiated in the vertical experimental channel of the ITP reactor for 48 hours. Induced radioactivity was 10 microcurie 59Fe. The preparation is suitable for use 4-5 days after irradiation.

В эксперименте при использовании препаратов радиоизотопа Fe максимальна  концентраци  в ткан х и органах наблюдалась через З.часа после применени . В дальнейшем она падала и через 36 ч приближалась к фоновой.In the experiment, when using preparations of the Fe radioisotope, the maximum concentration in tissues and organs was observed 3 hours after application. Subsequently, it fell and after 36 hours approached the background.

Возможность дозировани  - наведени  радиоактивности на препараты железа может значительно варьировать и в достаточно широких масштабах. При необходимости описанным способом можно приготовить препарат 59Fe с активностью до 100 и более микрокюри. Дл -получени  препаратов FeThe possibility of dosing - inducing radioactivity on iron preparations can vary significantly on a fairly wide scale. If necessary, the described method can be used to prepare 59Fe with an activity of up to 100 or more microcuries. For the preparation of Fe preparations

55

00

различной активности могут быть использованы исследовательские и промышленные  дерные реакторы. Мощность дозы зависит от характера патологического процесса, заболевани , возраста больного и его общего терапевтического статуса. Способ получени  препаратов дл  лечени  онкологических и иммунных заболеваний  вл етс  оригинальным, открывает новые перспективы лечени  г-групп больных ранее считавшихс  обреченными.various activities can be used research and industrial nuclear reactors. The dose rate depends on the nature of the pathological process, the disease, the age of the patient and his general therapeutic status. The method of preparing drugs for the treatment of cancer and immune diseases is original and opens up new prospects for the treatment of g-groups of patients previously considered doomed.

Важной особенностью полученных препаратов  вл етс  лечебное воздействие на все патологические очаги как обнаруженные в процессе исследовани  так и скрытые от него.An important feature of the preparations obtained is the therapeutic effect on all pathological foci, both detected during the study and hidden from it.

Claims (1)

Формула изобретени  Способ получени  противоопухолевого средства путем обработки железосодержащего препарата, отличающийс  тем, что, с целью повышени  активности конечного продукта, его облучают потоком нейтронов .SUMMARY OF THE INVENTION A method for producing an antitumor agent by treating an iron-containing preparation, characterized in that, in order to increase the activity of the final product, it is irradiated with a neutron flux.
SU914905853A 1991-01-31 1991-01-31 Method for preparation antitumor agent RU1837891C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SU914905853A RU1837891C (en) 1991-01-31 1991-01-31 Method for preparation antitumor agent
PCT/RO1992/000024 WO1992013563A1 (en) 1991-01-31 1992-01-31 Antitumoral preparation and method of making same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU914905853A RU1837891C (en) 1991-01-31 1991-01-31 Method for preparation antitumor agent

Publications (1)

Publication Number Publication Date
RU1837891C true RU1837891C (en) 1993-08-30

Family

ID=21557490

Family Applications (1)

Application Number Title Priority Date Filing Date
SU914905853A RU1837891C (en) 1991-01-31 1991-01-31 Method for preparation antitumor agent

Country Status (2)

Country Link
RU (1) RU1837891C (en)
WO (1) WO1992013563A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119138B2 (en) 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US7947275B2 (en) 2000-05-10 2011-05-24 Signe Biopharma, Inc. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US20030072812A1 (en) 2001-05-10 2003-04-17 Sirbasku David A Breast cancer eradication program
US7863011B2 (en) 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
EP1530720A4 (en) * 2001-11-13 2005-08-31 David A Sirbasku Breast cancer eradication program

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303636A (en) * 1974-08-20 1981-12-01 Gordon Robert T Cancer treatment
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
HU900222D0 (en) * 1990-01-22 1990-04-28 Peter Teleki Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells

Also Published As

Publication number Publication date
WO1992013563A1 (en) 1992-08-20

Similar Documents

Publication Publication Date Title
Raju Heavy particle radiotherapy
AU690616B2 (en) X-ray emitting interstitial implants
Schubert Removal of radioelements from the mammalian body
Lathrop et al. Rapid incorporation of short-lived cyclotron-produced radionuclides into radiopharmaceuticals
RU1837891C (en) Method for preparation antitumor agent
Harling et al. Boron neutron capture therapy and radiation synovectomy research at the Massachusetts Institute of Technology Research Reactor
Goodwin et al. Ferric hydroxide particles labeled with indium in 113m for lung scanning
Crabb et al. Metals and Life Chapter 9
RU2182022C1 (en) Method for treating oncological diseases of the thyroid gland
Ntoy et al. Calculation of BNCT dosimetry for brain cancer based on KARTINI research reactor using PHITS code
Kasbollah et al. Samarium-153 production using (n, γ) reaction at Triga Puspati research reactor
Chin et al. Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington
RU2174015C1 (en) Method for producing preparation and treating oncologic diseases
RU2053776C1 (en) Method of oncological disease treatment
Kautz et al. Radioactive drugs
Yang Precision Medicine and Theranostic Radioisotopes
Phelan Radioisotopes in medicine
Bewley Medical uses of cyclotrons: treatment and diagnosis
Patomäki Production of 18F for bone scanning
HILARIS THE FIRST 100 YEARS
De Wit et al. Description of an antique radium-goblet; a dangerous curiosity
Zaitsev et al. Neutron-capture therapy with thermal neutrons at the institute of radiation therapy at the Moscow engineering physics institute
Koprowski Response to Drs. Peschel and Wallner
Issachar et al. A new Os-191/Ir-191m generator for first-pass radionuclide angiography
Loken Karl Wilhelm Stenstrom, Ph. D. 1891–1973